On October 23, the Association of Clinical Research Organizations and the Congressional Research & Development Caucus hosted a Congressional Briefing on Capitol Hill about the advancements clinical research and technology companies are making in drug development.
WASHINGTON--(BUSINESS WIRE)-- On October 23, the Association of Clinical Research Organizations (ACRO) and the Congressional Research & Development Caucus hosted a Congressional Briefing on Capitol Hill about the advancements clinical research and technology companies are making in drug development. The briefing included representatives from ACRO member companies who discussed how they are driving 21st-century innovation in clinical trials through advancements such as real-world data and evidence, AI and novel patient-centered trial designs.
“Since the passage of the 21st Century Cures Act in 2016, the clinical research industry has seen great advancements in the way clinical trials are designed and run,” said Doug Peddicord, Executive Director at ACRO, and moderator of the Congressional Briefing. “Industry leaders are pushing to use innovative methods to assist in bringing molecules to market that will help patients faster.”
A panel of expert clinical research leaders included Jeff Allen, President and CEO of Friends of Cancer Research; Ari Feldman, Vice President of Global Compliance and Strategy at Medidata; Amrit Singh, Vice President of Global Infrastructure and Strategy at Bioclinica and Cyndi Verst, President of Design and Delivery Innovation, for the Research & Development Solutions organization at IQVIA.
“Technology should be able to make the patient’s experience better, enable better science, and hopefully bring more efficiency to clinical trials,” said Ari Feldman, Vice President of Global Compliance and Strategy at Medidata during the briefing. “We look forward to working together to press for innovative ways to integrate technology with the drug development process.”
About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics and medical devices. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 130,000 professionals worldwide and conduct or support the vast majority of clinical trials.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005130/en/
Contacts
Sophia McLeod smcleod@acrohealth.org
Source: Association of Clinical Research Organizations
View this news release online at:
http://www.businesswire.com/news/home/20191028005130/en
